Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022

SINGAPORE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced that Thomas Willemsen, President and CEO, and Dr. Ivan D. Horak, Chief Medical Officer and Chief Scientific Officer, will present at the Stifel Healthcare Conference 2022. The conference is taking place November 15-16, 2022, at Lotte New York Palace Hotel, New York City.

Details of the presentation are as follows:

Event:	Stifel Healthcare Conference 2022
Date:	Tuesday, November 15, 2022
Time:	8-8:30 a.m. ET
Location:	Lotte New York Palace Hotel, New York, NY

During the conference, Mr. Willemsen, Dr. Horak, and Wilson W. Cheung, Chief Financial Officer, will conduct one-on-one meetings with registered investors, showcasing Tessa’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

About Tessa Therapeutics  
Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b). TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency. Tessa is also advancing an allogeneic “off-the-shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state-of-the-art, commercial cell therapy manufacturing facility. For more information on Tessa, visit www.tessacell.com. 

Tessa Therapeutics Investor Contact 
Wilson W. Cheung 
Chief Financial Officer 
wcheung@tessacell.com